New: Introducing the Finviz Futures Map

Keros Therapeutics, Inc.

Contributing Author

Recent Articles by Keros Therapeutics, Inc.

Sep-08	Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting KROS GlobeNewswire
Aug-28	Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences KROS GlobeNewswire
Aug-20	Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy KROS GlobeNewswire
Aug-06	Keros to Exclusively Prioritize the Clinical Advancement of KER-065 KROS GlobeNewswire
Aug-06	Keros Therapeutics Reports Second Quarter 2025 Financial Results KROS GlobeNewswire
Jul-17	Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept KROS GlobeNewswire
Jun-09	Keros Announces Return of $375 Million in Excess Capital to Stockholders KROS GlobeNewswire
Jun-06	Keros Therapeutics Announces Participation at Goldman Sachs 46th Annual Global Healthcare Conference KROS GlobeNewswire
May-29	Keros Therapeutics Announces TROPOS Topline Data and Corporate Restructuring KROS GlobeNewswire
May-27	Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote "FOR" All of Keros' Director Nominees KROS GlobeNewswire
May-19	Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value KROS GlobeNewswire
May-12	Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference KROS GlobeNewswire
May-08	Keros Reinforces Commitment to Maximizing Stockholder Value KROS GlobeNewswire
May-06	Keros Therapeutics Reports Recent First Quarter 2025 Financial Results KROS GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.